PolyNovo 2026 AGM Report

ASX code	PNV
Meeting date	Friday, 30 October 2026
Type of meeting	Hybrid
Monitor	Christine Haydon with Gill Fryatt
Pre AGM-meeting	with Chair Leon Horne

Meeting Statistics

Number of holdings represented by ASA	21
Number of shares represented by ASA	1,302,413
Value of shares represented by ASA	$1.185m
Total number attending meeting	168 (43 in person, 125 online)
Market capitalisation	$625.05m
ASA open proxies voted	ASA voted in favour of all the resolutions

Monitor Shareholding: the individual involved in preparing this AGM report holds shares in the company.

PolyNovo reported revenue growth and strong operating cash flow in FY26. The company remained profitable, although net profit after tax declined from the previous year. There have been several changes in both Directors and key personnel with additional capabilities and skills to support growth in addition to the expanded manufacturing capability at Port Melbourne.

Post the fire of 2025 the R & D Innovation Centre has now been fully reoccupied with major milestones now complete. The company purpose is to redefine what is possible in healing with the core product regenerating tissue lost through burns, trauma or surgery.

130,000 patients have now been treated with the NovoSorb products. The company also has a humanitarian focus in war injury areas, such as Ukraine and Gaza. With the strong foundations now in place the products are developing further uses such as diabetic foot wounds and complex wounds and many other treatments where regenerating tissue is required.

There were several questions online by an unidentified person with seemingly sound knowledge of the organisation and approximately six questions in the room from shareholders.

ASA asked about director shareholder policy, individual Director skill sets on the skills matrix and the perceived weakness in technology, digital and cyber skills on the Board and its Audit and Risk Committee. On Remuneration it should be noted that a new LTI will be applicable for FY27 with three performance levels: threshold, target and outperform.

The Remuneration resolution passed with relatively low 85.5%, Director Dr Charmaine Gittleson received a poor 75%, Director Dean Phizacklea 98% and Director Andrew Price 99% favourable votes.

ASA Disclaimer

This document has been prepared by the Australian Shareholders Association Limited ABN 40 000 625 669 ("ASA"). It is not a disclosure document, it does not constitute investment or legal advice and it does not take into account any person's particular investment objectives. The statements and information contained in this document are not intended to represent recommendations of a particular course of action to any particular person. Readers should obtain their own independent investment and legal advice in relation to the matters contemplated by this document. To the fullest extent permitted by law, neither ASA nor any of its officers, directors, employees, contractors, agents or related bodies corporate:

- *makes any representations, warranties or guarantees (express or implied) as to the accuracy, reliability, completeness or fitness for purpose of any statements or information contained in this document; or*
- *shall have any liability (whether in contract, by reason of negligence or negligent misstatement or otherwise) for any statements or information contained in, or omissions from this document; nor for any person's acts or omissions undertaken or made in reliance of any such statements, information or omissions.*

This document may contain forward looking statements. Such statements are predictions only and are subject to uncertainties. Given these uncertainties, readers are cautioned not to place reliance on any such statements. Any such statements speak only to the date of issue of this document and ASA disclaims any obligation to disseminate any updates or revisions to any such statements to reflect changed expectations or circumstances.